ESMO 2026: What’s New in Melanoma Immunotherapy?
This overview examines findings from IOV-COM-202, MIZAR-003, and PLUG-IN GEM 2301, with attention to efficacy, safety, and the limitations of each study. Final results from cohort 1A of IOV-COM-202 showed encouraging activity with lifileucel plus pembrolizumab in immune checkpoint inhibitor (ICI)-naïve advanced…